Skip to main content

SEROLOGICAL TESTING AND TREATMENT FOR P. VIVAX: FROM A CLUSTER-RANDOMISED TRIAL IN ETHIOPIA AND MADAGASCAR TO A MOBILE-TECHNOLOGY SUPPORTED INTERVENTION

Objective

P. vivax is considered the most difficult human malaria to eliminate because of the inability of conventional diagnostics to detect individuals with latent liver forms. These individuals account for 80% of all infections and can readily infect mosquitoes. Currently countries can test knowing this has little impact or and the treat everyone which exposes individuals to drugs with potentially dangerous side effects. Parasite specific antibody responses have been shown to correlate with the likelihood of hypnozoite carriage and can be used to identify individuals who should be treated.

Aim is to implement a Cluster-Randomised Trial in Ethiopia and Madagascar to demonstrate the effectiveness of a new anti-malaria intervention based on Plasmodium vivax serological testing and treatment (PvSTATEM) with primaquine to prevent the relapse infections responsible for maintaining P. vivax transmission. Simultaneously, we will assess social and health system acceptability of such an approach as well as refine new mobile technologies which interface with point-of-care diagnostic tests and guide treatment decisions.

We aim to reduce malaria burden at both the individual and population level in two countries which experience the highest levels of P.vivax in Africa. We expect to have a significant effect in reducing morbidity and improving health. We will ensure community engagement and assess the adoption of new technologies that align with those existing in the health system. The proposal is built on equal partnership and shared capacity to address a substantial public health burden.

Coordinator

INSTITUT PASTEUR
Net EU contribution
€ 1 810 815,99
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 0,00

Participants (5)

ARMAUER HANSEN RESEARCH INSTIUTE
Ethiopia
Net EU contribution
€ 2 062 425,99
Address
Jimma Road Alert Compound
1005 Addis Ababa

See on map

Activity type
Research Organisations
Other funding
€ 0,00
Institut Pasteur de Madagascar
Madagascar
Net EU contribution
€ 2 050 509,91
Address
Ambatofotsikely - Avaradoha
101 Antananarivo

See on map

Activity type
Research Organisations
Other funding
€ 0,00
NATIONAL UNIVERSITY OF IRELAND GALWAY
Ireland
Net EU contribution
€ 282 600,00
Address
University Road
H91 Galway

See on map

Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS
Switzerland
Net EU contribution
€ 409 700,50
Address
Campus Biotech, Chemin Des Mines 9
1202 Geneve

See on map

Region
Schweiz/Suisse/Svizzera Région lémanique Genève
Activity type
Other
Other funding
€ 0,00
MEDEA SRL
Italy
Net EU contribution
€ 178 375,00
Address
Via Massa Avenza 38/b
54100 Massa Ms

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Centro (IT) Toscana Massa-Carrara
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00

Partners (2)

THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH PUBLIC COMPANYLIMITED BY GUARANTEE
Australia
Net EU contribution
€ 0,00
Other funding
€ 0,00
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
United Kingdom
Net EU contribution
No data
Address
Keppel Street
WC1E 7HT London

See on map

Region
London Inner London — West Camden and City of London
Activity type
Higher or Secondary Education Establishments
Other funding
No data